Terumasa Yamada

Terumasa Yamada

Auto-generated profile, based on publicly available information

Terumasa Yamada

Department of Gastroenterological Surgery, Higashiosaka City Medical Center, Higashiosaka, Japan

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2006 in Surgery
Verified
Journal Article
Closed access
PDF file
HEHidetoshi Eguchi
Hidetoshi Eguchi
OIOsamu Ishikawa
Osamu Ishikawa
HOHiroaki Ohigashi
Hiroaki Ohigashi
YTYoshito Tomimaru
Yoshito Tomimaru
YSYo Sasaki
Yo Sasaki
SIShingi Imaoka
Shingi Imaoka

30 August 2018 in Surgery Today
Verified
Journal Article
Closed access
PDF file
SEShunji Endo
Shunji Endo
MIMasakazu Ikenaga
Masakazu Ikenaga
KOKatsuya Ohta
Katsuya Ohta
MUMasami Ueda
Masami Ueda
YTYujiro Tsuda
Yujiro Tsuda
TYTerumasa Yamada
Terumasa Yamada

1 March 2022 in Pancreas
Verified
Journal Article
Closed access
KIKiyotsugu Iede
Kiyotsugu Iede
TYTerumasa Yamada
Terumasa Yamada
MKMasahiro Koh
Masahiro Koh
MUMasami Ueda
Masami Ueda
YTYujiro Tsuda
Yujiro Tsuda
STShusei Tominaga
Shusei Tominaga
Objective: Second-line (2L) chemotherapy is important for improved survival in patients with advanced pancreatic cancer (APC). However, approximately half of patients with APC do not receive 2L chemotherapy because of disease progression or adverse events. Baseline factors predictive of the receipt of 2L chemotherapy remain unknown. Therefore, we investigated predictive factors for the receipt of 2L chemotherapy in patients with APC. Methods: Between January 2015 and March 2020, 53 patients with APC received nab-paclitaxel plus gemcitabine (AG) as first-line chemotherapy at our institute. Of these 53 patients, 29 patients received 2L chemotherapy, and 23 patients received best supportive care. Patients' characteristics were compared retrospectively, and predictive factors for the receipt of 2L chemotherapy were evaluated. Results: Sarcopenia and hypoalbuminemia at baseline were independent negative predictive factors for the receipt of 2L chemotherapy in multivariate analysis. Although the presence of sarcopenia did not affect the relative dose intensity through 8 weeks of AG therapy, patients with hypoalbuminemia had a significantly lower relative dose intensity. Conclusions: Sarcopenia and hypoalbuminemia at baseline might be negative predictive factors for the receipt of 2L chemotherapy after AG treatment in patients with APC.

28 August 2019 in Cancer Reports
Verified
Journal Article
Open access
PDF file
KIKiyotsugu Iede
Kiyotsugu Iede
TYTerumasa Yamada
Terumasa Yamada
RKRyo Kato
Ryo Kato
MUMasami Ueda
Masami Ueda
YTYujiro Tsuda
Yujiro Tsuda
STShusei Tominaga
Shusei Tominaga
Background: Second‐line (2 L) chemotherapy is important for improved survival. However, the efficacy of S‐1 after nab‐paclitaxel plus gemcitabine (AG) for advanced pancreatic cancer (APC) remains unclear.Aim: We retrospectively investigated the clinical impact of S‐1 after AG.Methods and results: From January 2015 to July 2018, 37 patients with APC underwent AG as first‐line chemotherapy at our institute. Of these patients, 14 (38%) underwent S‐1 as 2 L chemotherapy after AG (S‐1 group), five (14%) received another agent after AG, and 18 (49%) underwent no 2 L chemotherapy (best supportive care [BSC] group). The clinical features were retrospectively compared between the S‐1 and BSC groups. Prognostic factors for residual survival (RS) were analyzed using a Cox proportional hazards model. The induction rate of 2 L chemotherapy was 51%, and most patients received S‐1 monotherapy (74%). The disease control rate and progression‐free survival duration were 57.1% and 2.8 months, respectively. The median RS duration in the S‐1 and BSC groups was 5.2 and 2.4 months, respectively; this difference was statistically significant (hazard ratio, 0.33; P = .005). The median overall survival duration in the S‐1 and BSC groups was 12.3 and 5.0 months, respectively; this difference was also statistically significant (hazard ratio, 0.26; P = .001). The efficacy of S‐1 in 2L chemotherapy for RS was identified in the multivariate analysis, as was age (<65 vs ≥65 y) and the presence of liver metastasis.Conclusion: The antitumor activity of S‐1 was retained after AG, and the induction of S‐1 after AG might improve the prognosis of patients with APC.

1 January 2019 in International Journal of Surgery Case Reports
Verified
Journal Article
Open access
SNShinsuke Nakashima
Shinsuke Nakashima
TYTerumasa Yamada
Terumasa Yamada
GSGo Sato
Go Sato
TSTakaaki Sakai
Takaaki Sakai
YCYoshinao Chinen
Yoshinao Chinen
MIMasakazu Ikenaga
Masakazu Ikenaga
Enteric duplication cysts are rare and, in addition, isolated enteric duplication cysts are lower morbidity prevalence rate. These cysts lack a connection to the gastrointestinal tract or the adjacent mesenteric vasculature and have only been reported in 10 case reports. In these reports, only two reports were cases with malignant transformation. Our case was a report for the advanced cancer of the isolated enteric duplication cyst. The patient was a 43 year-old woman with slightly abdominal pain and mass formation. The abdominal contrast-enhanced computed tomography showed 130 × 100 × 90 mm huge cystic mass existed in right upper peritoneal cavity. The cystic mass had thickened wall and many enhanced nodules. As these imaging findings suggested a tumor originated from pancreas and the preoperative diagnose was suspect of mucinous cystic neoplasm. In operative findings, the tumor originated from pancreatic head and did not attach to gastrointestinal tract. Final pathology indicated the cyst was an isolated advanced enteric duplication cyst cancer and not originated from pancreas. We experienced an extremely rare case of completely isolated advanced enteric duplication cyst cancer. Unique to this case, the preoperative diagnosis was suspect of mucinous cystic neoplasm arising from pancreas head and partial pancreatectomy was performed. However, in the pathological findings, this cyst diagnosed advanced enteric duplication cyst cancer.

22 July 2022 in Medicine
Verified
Journal Article
Open access
KIKiyotsugu Iede
Kiyotsugu Iede
TYTerumasa Yamada
Terumasa Yamada
MUMasami Ueda
Masami Ueda
YTYujiro Tsuda
Yujiro Tsuda
SNShinsuke Nakashima
Shinsuke Nakashima
STShusei Tominaga
Shusei Tominaga
Although the antitumor effects of antihypertensive drugs for patients with advanced pancreatic cancer (APC) have been investigated, their efficacy remains unclear. Previous studies suggest that hypertensive (HT) patients with APC are significantly older than non-HT patients with APC, and that other major baseline differences in patient characteristics which may affect prognosis exist between HT and non-HT patients. It is also possible that antihypertensive drugs lack antitumor activity. Therefore, we herein retrospectively investigated the baseline differences between HT and non-HT patients with APC. From January 2015 to April 2020, 56 patients with APC received nab-paclitaxel plus gemcitabine as first-line chemotherapy at Higashiosaka City Medical Center (Higashiosaka, Japan). Of these 56 patients, 30 were diagnosed with hypertension (HT group); the remaining 26 did not have hypertension (non-HT group). Differences between the two groups were compared and prognostic factors were evaluated. Patients in the HT group had significantly less sarcopenia, a significantly larger body mass index, were significantly older, and significantly more likely to have a regular doctor and primary site in the body and tail of the pancreas than those in the non-HT group. Although no significant difference was found in the treatment response, patients in the HT group were significantly more likely to move to second-line chemotherapy than those in the non-HT group. Survival curves showed that median overall survival (OS) in the HT group was significantly longer (10.5 months) than in the non-HT group (6.8 months, P = .04). Multivariate analysis did not identify the use of antihypertensive drugs as an independent prognostic factor of OS. We identified key baseline differences in the characteristics of APC patients with and without HT, suggesting that major selection bias could occur when investigating the efficacy of antihypertensive drugs in all populations. Therefore, it is possible that antihypertensive drugs lack antitumor activity. To determine the true efficacy of antihypertensive drugs for APC, HT, and non-HT patients in another population should be investigated, or a prospective, randomized, controlled trial conducted that is stratified by HT or non-HT status.